Werewolf Therapeutics Inc

NASDAQ HOWL

Data sourced from

and

Download Data

Werewolf Therapeutics Inc Cash Interest Coverage Ratio 3 year CAGR for the quarter ending March 31, 2024: -58.58%

Werewolf Therapeutics Inc Cash Interest Coverage Ratio 3 year CAGR is -58.58% for the quarter ending March 31, 2024. The cash interest coverage ratio measures a company's ability to cover its interest expenses with its operating cash flow. It is calculated by dividing operating cash flow by interest expense. This ratio indicates the company's capacity to generate sufficient cash flow to meet its interest obligations. A higher ratio signifies better coverage and financial stability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Werewolf Therapeutics Inc Cash Interest Coverage Ratio for the quarter ending March 31, 2023 was 14.86, a 102.45% change year over year.
Werewolf Therapeutics Inc Cash Interest Coverage Ratio for the quarter ending March 31, 2022 was -606.57, a -173.23% change year over year.
Werewolf Therapeutics Inc Cash Interest Coverage Ratio for the quarter ending March 31, 2021 was -222.00, a -337.60% change year over year.
Werewolf Therapeutics Inc Cash Interest Coverage Ratio for the quarter ending March 31, 2020 was -50.73.

NASDAQ: HOWL

Werewolf Therapeutics Inc

CEO	Dr. Daniel J. Hicklin Ph.D.
IPO Date	April 30, 2021
Location	United States
Headquarters	1030 Massachusetts Avenue, Cambridge, MA, United States, 02138
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Key trends